Hanssens LS, Duchateau J, Casimir GJ (2021) CFTR protein: not just a chloride channel? Cells. https://doi.org/10.3390/cells10112844

Article  PubMed  PubMed Central  Google Scholar 

Bergeron C, Cantin AM (2019) Cystic fibrosis: pathophysiology of lung disease. Semin Respir Crit Care Med 40(6):715–726. https://doi.org/10.1055/s-0039-1694021

Article  PubMed  Google Scholar 

Witko-Sarsat V, Burgel PR (2024) Cystic fibrosis in the era of CFTR modulators: did the neutrophil slip through the cracks? J Leukocyte Biol 115(3):417–419. https://doi.org/10.1093/jleuko/qiad164

Article  PubMed  Google Scholar 

Groves DT, Jiang Y (1995) Chemokines, a family of chemotactic cytokines. Crit Rev Oral Biol Med 6(2):109–118. https://doi.org/10.1177/10454411950060020101

Article  Google Scholar 

Sagel SD, Wagner BD, Anthony MM, Emmett P, Zemanick ET (2012) Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med 186(9):857–865. https://doi.org/10.1164/rccm.201203-0507OC

Article  CAS  PubMed  PubMed Central  Google Scholar 

Laval J, Ralhan A, Hartl D (2016) Neutrophils in cystic fibrosis. Biol Chem 397(6):485–496. https://doi.org/10.1515/hsz-2015-0271

Article  CAS  PubMed  Google Scholar 

Jundi K, Greene CM (2015) Transcription of interleukin-8: how altered regulation can affect cystic fibrosis lung disease. Biomolecules 5(3):1386–1398. https://doi.org/10.3390/biom5031386

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group (2019) Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 394(10212):1940–1948. https://doi.org/10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31. Erratum in: Lancet. 2020;395(10238):1694. https://doi.org/10.1016/S0140-6736(20)31021-7

Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA, VX18-445-109 study group (2022) Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Lancet Respir Med 10(3):267–277. https://doi.org/10.1016/S2213-2600(21)00454-9

Article  CAS  PubMed  Google Scholar 

Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R, VX17-445-102 Study Group (2019) Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 381(19):1809–1819. https://doi.org/10.1056/NEJMoa1908639

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taylor-Cousar JL, Mall MA, Ramsey BW et al (2019) Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. ERJ Open Res 5:00082–02019. https://doi.org/10.1183/23120541.00082-2019

Article  PubMed  PubMed Central  Google Scholar 

Wainwright C, McColley SA, McNally P, Powers M, Ratjen F, Rayment JH, Retsch-Bogart G, Roesch E, Ahluwalia N, Chin A, Chu C, Lu M, Menon P, Waltz D, Weinstock T, Zelazoski L, Davies JC (2023) Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children aged ⩾6 years with cystic fibrosis and at least one F508del Allele: a phase 3, open-label clinical trial. Am J Respir Crit Care Med 208(1):68–78. https://doi.org/10.1164/rccm.202301-0021OC

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daines CL, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS, Ringshausen FC, Rowe SM, Selvadurai H, Taylor-Cousar JL, Withers NJ, Ahluwalia N, Moskowitz SM, Prieto-Centurion V, Tan YV, Tian S, Weinstock T, Xuan F, Zhang Y, Ramsey B, Griese M, VX17-445-105 Study Group (2023) Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study. Eur Respir J 62(6):2202029. https://doi.org/10.1183/13993003.02029-2022

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keens T, Hoffman V, Topuria I, Elder K, Cerf S, Mulder K, Roberts J, Lysinger J, Del Carmen RM, Berdella M, Cairns AM, Jain M, Ganapathy V, Lou Y, Morcos B, Wu C, Sass L, VX19-CFD-003 Study Group (2024) Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis. Heliyon 10(7):e28508. https://doi.org/10.1016/j.heliyon.2024.e28508

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thimmesch M, Meurrens J, Tataris A, Pirson J, Tamigniau A (2024) Évolution du test de la sueur chez les patients atteints de mucoviscidose traités par elexacaftor/tezacaftor/ivacaftor [sweat test evolution in cystic fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor]. Rev Med Liege 79(11):716–718

PubMed  Google Scholar 

Shoki AH, Mayer-Hamblett N, Wilcox PG et al (2013) Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. Chest 144:1659–1670. https://doi.org/10.1378/chest.13-0693

Article  CAS  PubMed  Google Scholar 

Schaupp L, Addante A, Völler M et al (2023) Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. Eur Respir J 62:2202153. https://doi.org/10.1183/13993003.02153-2022

Article  CAS  PubMed  Google Scholar 

Einarsson GG, Ronan NJ, Mooney D et al (2021) Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor. J Cyst Fibros 20:747–753. https://doi.org/10.1016/j.jcf.2020.12.023

Article  CAS  PubMed  Google Scholar 

Mainz JG, Arnold C, Wittstock K et al (2021) Ivacaftor reduces inflammatory mediators in upper airway lining fluid from cystic fibrosis patients with a G551D mutation: serial non-invasive home-based collection of upper airway lining fluid. Front Immunol 12:642180. https://doi.org/10.3389/fimmu.2021.642180

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruffin M, Roussel L, Maillé É et al (2018) Vx-809/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 314:L635–L641. https://doi.org/10.1152/ajplung.00198.2017

Article  CAS  PubMed  Google Scholar 

Jarosz-Griffiths HH, Scambler T, Wong CH et al (2020) Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis. Elife 9:e54556. https://doi.org/10.7554/eLife.5455

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sheikh S, Britt RD Jr, Ryan-Wenger NA, Khan AQ, Lewis BW, Gushue C, Ozuna H, Jaganathan D, McCoy K, Kopp BT (2023) Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis. Pediatr Pulmonol 58(3):825–833. https://doi.org/10.1002/ppul.26261

Article  PubMed  Google Scholar 

Dhote T, Martin C, Regard L, Pesenti L, Kanaan R, Carlier N, Honoré I, Da Silva J, Witko-Sarsat V, Burgel PR (2023) Normalisation of circulating neutrophil counts after 12 months of elexacaftor-tezacaftor-ivacaftor in patients with advanced cystic fibrosis. Eur Respir J 61(1):2202096. https://doi.org/10.1183/13993003.02096-2022

Article  PubMed  Google Scholar 

Jarosz-Griffiths HH, Gillgrass L, Caley LR, Spoletini G, Clifton IJ, Etherington C, Savic S, McDermott MF, Peckham D (2024) Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del. PLoS ONE 19(5):e0304555. https://doi.org/10.1371/journal.pone.0304555

Article  CAS  PubMed  PubMed Central  Google Scholar 

BaniMelhim S, Douglas LEJ, Reihill JA, Downey DG, Martin SL (2024) The effect of triple CFTR modulator therapy and azithromycin on ion channels and inflammation in cystic fibrosis. ERJ Open Res 10(6):00502–02024. https://doi.org/10.1183/23120541.00502-2024

Article  Google Scholar 

Casey M, Gabillard-Lefort C, McElvaney OF, McElvaney OJ, Carroll T, Heeney RC, Gunaratnam C, Reeves EP, Murphy MP, McElvaney NG (2023) Effect of elexacaftor/tezacaftor/ivacaftor on airway and systemic inflammation in cystic fibrosis. Thorax 78(8):835–839. https://doi.org/10.1136/thorax-2022-219943

Article  PubMed  Google Scholar 

Atteih SE, Armbruster CR, Hilliam Y, Rapsinski GJ, Bhusal JK, Krainz LL, Gaston JR, DuPont M, Zemke AC, Alcorn JF, Moore JA, Cooper VS, Lee SE, Forno E, Bomberger JM (2024) Effects of highly effective modulator therapy on the dynamics of the respiratory mucosal environment and inflammatory response in cystic fibrosis. Pediatr Pulmonol 59(5):1266–1273. https://doi.org/10.1002/ppul.26898